Technology Assessment

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Technology Assessment

Mercury Pharmaceuticals

The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow etc., the economic value needs to be demonstrated to healthcare payers.

Using Health Technology Assessment, the value of a novel medical intervention is quantified by simultaneous analysis of effects on patient outcomes and total costs of care associated with the innovation in comparison to the standard of care. An objective measure of the medical innovation’s value is generally required for (national) reimbursement applications.

Mercury Pharmaceuticals offers tailor-made Health Technology Assessment expertise through:

    Mercury Pharmaceuticals
  • Development-focused health technology assessment: even in the early stages of development when complete clinical data is not (yet) available, an estimation of expected value can be made using experts-inputs and small scale studies
  • Extensive literature review of the relevant standard of care pathway and associated costs, establishing the baseline to which your innovation will be compared by payers
  • Developing, analyzing and validating health economic models, including translating and updating  existing models with new (country-specific) data
  • Development of value dossiers for all relevant stakeholders
  • Preparation of reimbursement files

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

AI scribe survey reveals patient preferences for medical note-taking

17

Dec 2025

AI scribe survey reveals patient preferences for medical note-taking

Electronic medical records (EMRs) have been a tremendous benefit in exam rooms across the country, creating secure patient history databases that clinicians can easily access and update. Yet, they can also detract from the doctor-patient experience, as physicians must type notes into the system rather than devote their complete attention to patients.

READ MORE
Study shows iCTG improves perinatal outcomes in resource-constrained settings

17

Dec 2025

Study shows iCTG improves perinatal outcomes in resource-constrained settings

Ninety-nine percent of global newborn deaths occur in low- and middle-income countries (LMICs), where pregnant women often struggle to access adequate fetal monitoring. In Tanzania, with 24 neonatal deaths per 1000 live births, a new wireless fetal heart rate monitoring technology is showing promise in preventing newborn complications and deaths.

READ MORE

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.